Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia

Lazaros Lekakis, Marcos de Lima

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Acute myeloid leukemia (AML) is a hematologic malignancy with a peak incidence over the age of 55 years. AML of older patients is less curable with conventional chemotherapy, and, when it relapses, is almost uniformly fatal. Novel treatments hold the promise of improving the results of therapy, but have failed so far to show dramatic change in the prognosis. Allogeneic stem cell transplantation using traditional myeloablative preparative regimens is not easily tolerated by the elderly and/or frailer patient, and may lead to prohibitive treatment-related mortality rates. Most patients treated in the past were younger and devoid of comorbid clinical conditions. Novel reduced-intensity regimens made allogeneic transplants applicable to the elderly, providing the benefit of the graft-versus-leukemia effect to a larger number of patients in need. Here we review the indications for allogeneic transplants in AML and discuss reduced-intensity conditioning regimens.

Original languageEnglish
Pages (from-to)785-798
Number of pages14
JournalExpert Review of Anticancer Therapy
Volume8
Issue number5
DOIs
StatePublished - Aug 29 2008
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Acute Myeloid Leukemia
Transplants
Frail Elderly
Stem Cell Transplantation
Hematologic Neoplasms
Leukemia
Therapeutics
Recurrence
Drug Therapy
Mortality
Incidence

Keywords

  • Acute myeloid leukemia
  • Altogeneic stem cell transplantation
  • Nonmyetoablative
  • Reduted-intensity conditioning

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research

Cite this

Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. / Lekakis, Lazaros; de Lima, Marcos.

In: Expert Review of Anticancer Therapy, Vol. 8, No. 5, 29.08.2008, p. 785-798.

Research output: Contribution to journalArticle

@article{0c92585c968949b1adf24e2794082025,
title = "Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia",
abstract = "Acute myeloid leukemia (AML) is a hematologic malignancy with a peak incidence over the age of 55 years. AML of older patients is less curable with conventional chemotherapy, and, when it relapses, is almost uniformly fatal. Novel treatments hold the promise of improving the results of therapy, but have failed so far to show dramatic change in the prognosis. Allogeneic stem cell transplantation using traditional myeloablative preparative regimens is not easily tolerated by the elderly and/or frailer patient, and may lead to prohibitive treatment-related mortality rates. Most patients treated in the past were younger and devoid of comorbid clinical conditions. Novel reduced-intensity regimens made allogeneic transplants applicable to the elderly, providing the benefit of the graft-versus-leukemia effect to a larger number of patients in need. Here we review the indications for allogeneic transplants in AML and discuss reduced-intensity conditioning regimens.",
keywords = "Acute myeloid leukemia, Altogeneic stem cell transplantation, Nonmyetoablative, Reduted-intensity conditioning",
author = "Lazaros Lekakis and {de Lima}, Marcos",
year = "2008",
month = "8",
day = "29",
doi = "10.1586/14737140.8.5.785",
language = "English",
volume = "8",
pages = "785--798",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia

AU - Lekakis, Lazaros

AU - de Lima, Marcos

PY - 2008/8/29

Y1 - 2008/8/29

N2 - Acute myeloid leukemia (AML) is a hematologic malignancy with a peak incidence over the age of 55 years. AML of older patients is less curable with conventional chemotherapy, and, when it relapses, is almost uniformly fatal. Novel treatments hold the promise of improving the results of therapy, but have failed so far to show dramatic change in the prognosis. Allogeneic stem cell transplantation using traditional myeloablative preparative regimens is not easily tolerated by the elderly and/or frailer patient, and may lead to prohibitive treatment-related mortality rates. Most patients treated in the past were younger and devoid of comorbid clinical conditions. Novel reduced-intensity regimens made allogeneic transplants applicable to the elderly, providing the benefit of the graft-versus-leukemia effect to a larger number of patients in need. Here we review the indications for allogeneic transplants in AML and discuss reduced-intensity conditioning regimens.

AB - Acute myeloid leukemia (AML) is a hematologic malignancy with a peak incidence over the age of 55 years. AML of older patients is less curable with conventional chemotherapy, and, when it relapses, is almost uniformly fatal. Novel treatments hold the promise of improving the results of therapy, but have failed so far to show dramatic change in the prognosis. Allogeneic stem cell transplantation using traditional myeloablative preparative regimens is not easily tolerated by the elderly and/or frailer patient, and may lead to prohibitive treatment-related mortality rates. Most patients treated in the past were younger and devoid of comorbid clinical conditions. Novel reduced-intensity regimens made allogeneic transplants applicable to the elderly, providing the benefit of the graft-versus-leukemia effect to a larger number of patients in need. Here we review the indications for allogeneic transplants in AML and discuss reduced-intensity conditioning regimens.

KW - Acute myeloid leukemia

KW - Altogeneic stem cell transplantation

KW - Nonmyetoablative

KW - Reduted-intensity conditioning

UR - http://www.scopus.com/inward/record.url?scp=45849102069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45849102069&partnerID=8YFLogxK

U2 - 10.1586/14737140.8.5.785

DO - 10.1586/14737140.8.5.785

M3 - Article

C2 - 18471050

AN - SCOPUS:45849102069

VL - 8

SP - 785

EP - 798

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 5

ER -